An Ohio court reversed a previous ruling forcing a hospital to administer ivermectin to a patient with Covid-19. “[Le médicament] has not proven its effectiveness at this stage ”, justified another magistrate.
A US court has made a turnaround, ultimately refusing to force a hospital to administer ivermectin to a patient infected with Covid-19. “[Le médicament] has not proven effective at this point, ”Judge Michael Oster of Butler County, Ohio wrote in his Sept. 6 decision.
The magistrate thus takes the opposite view of another decision rendered two weeks ago by another magistrate who, at the request of the patient’s wife, had forced the hospital to administer ivermectin. The patient’s wife had taken legal action after a first refusal from the establishment.
“The medical and scientific communities do not today support the use of ivermectin as a treatment for Covid-19”, he recalls. As reported by AFP, he thus justifies his decision by emphasizing “the limits” of studies favorable to this product, some of which “have even had to be withdrawn”. “Although this court […] understand the idea of doing everything to help [un] loved one, public policy should not and does not support allowing a doctor to try “any” type of treatment on human beings, “said the judge quoted by the Huffington Post.
Despite the WHO’s disavowal, the drug has already met with success in several countries such as Brazil, Lebanon and South Africa. In Indonesia, AFP reports that pharmacies are facing a rush on ivermectin. In India, a collective of lawyers from Bombay has announced that it is launching a lawsuit against Soumya Swaminathan, a pediatrician specializing in tuberculosis and scientific director of the WHO. Indian lawyers accuse him of dismissing evidence in favor of ivermectin, of having tweeted advising against its use (which they equate to disinformation leading to deaths), and of promoting laboratories that produce vaccines.
On July 12, the Institut Pasteur unveiled a study on the effects of this antiparasitic treatment against Covid-19, which concludes that “taking this drug at standard doses makes it possible to reduce the symptoms and severity in an animal model. of SARS-CoV-2 infection ”. On the other hand, according to this study, the treatment does not seem to act on viral replication.